Product image of Ikatibant Teva (Icatibant Acetate) supplied by GNH India

Ikatibant Teva

Active Ingredient:
Icatibant Acetate
Origin:
EU

Ikatibant Teva (Icatibant Acetate)

Icatibant acetate, the active ingredient in Ikatibant Teva, is a bradykinin B2 receptor antagonist presented as a sterile solution for subcutaneous injection. It is indicated for the treatment of acute attacks of hereditary angioedema in patients with C1‑inhibitor deficiency, helping to reduce swelling and associated discomfort.

GNH India supplies Ikatibant Teva as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide, with a focus on reliable sourcing for the European market and other regulated regions.

Manufacturer / TM Owner

Teva B.V

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ikatibant Teva acts on the bradykinin pathway to relieve swelling in hereditary angioedema.

  • Hereditary angioedema type I: rapid reduction of swelling during acute attacks.
  • Hereditary angioedema type II: rapid reduction of swelling during acute attacks.
  • Hereditary angioedema with normal C1‑inhibitor (off‑label): may be considered under specialist supervision.

How It Works

  • Icatibant acetate selectively blocks the bradykinin B2 receptor on vascular endothelial cells, preventing bradykinin‑mediated vasodilation and increased vascular permeability. By inhibiting this receptor, the drug reduces the fluid extravasation that causes the characteristic swelling of hereditary angioedema attacks.

Side Effects

Ikatibant Teva may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

  • Injection site pain: discomfort at the injection site.
  • Injection site erythema: redness around the injection area.
  • Injection site swelling: localized edema.
  • Nausea: mild gastrointestinal upset.
  • Headache: transient head discomfort.
  • Dizziness: light‑headed sensation.

Serious or Rare Side Effects

  • Hypersensitivity reactions: rash, itching, or swelling of the face.
  • Anaphylaxis: severe, life‑threatening allergic response.
  • Severe hypotension: marked drop in blood pressure.
  • Angioedema unrelated to HAE: unexpected swelling.
  • Thrombocytopenia: reduced platelet count.
  • Injection‑site infection: signs of local infection.

Precautions & Warnings

Before prescribing Ikatibant Teva, clinicians should consider several safety measures.

  • Assess patient history: confirm diagnosis of hereditary angioedema.
  • Monitor for hypersensitivity: watch for rash, itching, or breathing difficulty.
  • Avoid in patients with known hypersensitivity to icatibant acetate.
  • Use with caution in pregnant or breastfeeding women: limited safety data are available.
  • Do not mix with other injectable solutions in the same syringe.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Ikatibant Teva can interact with other medicines, requiring attention to potential additive effects.

Major Interactions (Avoid)

  • Concurrent use with ACE inhibitors: may increase bradykinin levels and raise the risk of angioedema.
  • Co‑administration with other bradykinin B2 antagonists: additive antagonism is not recommended.

Moderate Interactions (Monitor Closely)

  • Concurrent use with other subcutaneous biologics: monitor injection‑site reactions.
  • Use with antihistamines or corticosteroids: may mask early signs of hypersensitivity.
  • Use with diuretics: monitor blood pressure for unexpected changes.

Frequently Asked Questions

Ikatibant Teva is used to treat acute attacks of hereditary angioedema (HAE) in patients who have a deficiency of C1‑inhibitor. By rapidly reducing swelling, it helps relieve the painful and potentially dangerous symptoms associated with HAE episodes.

Icatibant acetate works by selectively blocking the bradykinin B2 receptor on blood vessel walls. This inhibition prevents bradykinin‑induced vasodilation and increased vascular permeability, which are the primary mechanisms that cause the swelling seen in hereditary angioedema attacks.

The dose of Ikatibant Teva is determined by the prescribing clinician based on the patient’s condition, weight, and severity of the HAE attack. The medication is administered as a subcutaneous injection, and the exact regimen should follow the prescriber’s instructions.

Safety data for icatibant acetate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Ikatibant Teva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

The primary alternative for acute HAE attacks is C1‑inhibitor concentrate, a plasma‑derived or recombinant protein that replaces the deficient inhibitor. Icatibant, as a small‑molecule B2‑receptor antagonist, works downstream of bradykinin and can be administered subcutaneously, offering a rapid, needle‑sized option without the need for intravenous infusion.

Ikatibant Teva should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and potency.

Ikatibant Teva is given as a single subcutaneous injection into the abdomen or thigh. The injection is performed by a healthcare professional or a trained patient, following aseptic technique and the dosage instructions provided by the prescriber.

Serious risks include hypersensitivity reactions such as anaphylaxis, severe hypotension, and rare cases of angioedema unrelated to hereditary angioedema. Patients should be monitored closely after injection for any signs of allergic response or cardiovascular changes.

Ikatibant Teva should not be used by individuals with a known hypersensitivity to icatibant acetate or any of its excipients. It is also contraindicated in patients who are currently receiving other bradykinin B2 receptor antagonists.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Icatibant Acetate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT